| dc.creator |
ASLAN KOŞAR, Pınar |
|
| dc.creator |
YAVUZ TÜREL, Gülçin |
|
| dc.date |
2024-01-01T00:00:00Z |
|
| dc.date.accessioned |
2025-02-25T10:32:47Z |
|
| dc.date.available |
2025-02-25T10:32:47Z |
|
| dc.identifier |
7dec1e09-6b0e-46f0-8682-9ffe53ded1a6 |
|
| dc.identifier |
10.1080/01480545.2024.2375300 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/7dec1e09-6b0e-46f0-8682-9ffe53ded1a6/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/100290 |
|
| dc.description |
Ramelteon (RMLT) is a melatonin receptor agonist that it has antioxidative and anti-inflammatory effects associated with DNA damage through different mechanisms of action. In this regard, we investigated the potential usefulness of RMLT as a protective agent against methotrexate (MTX)-induced DNA damage. Four groups were constituted from 32 Wistar albino rats: Negative control, RMLT, MTX, and MTX + RMLT. Twenty mg/kg MTX (i.p., single dose) and RMLT 10 mg/kg (oral, 7 days) was administered. Comet assay was used and the parameter %TailDNA was used to detect DNA damage. %TailDNA was 4.90 ± 0.19 in the control group, 7.85 ± 0.33 in the MTX group, 5.49 ± 0.24 in the RMLT group, and 5.86 ± 0.23 in the MTX + RMLT group. While there was a significant increase in DNA damage in the MTX-treated group compared to the control group, there was a significant reduction in DNA damage in the MTX + RMLT group, compared to the MTX group (p < 0.001). In conclusion, it was observed that combined treatment with RMLT significantly reduced MTX-induced DNA damage. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Protective efficacy of ramelteon on methotrexate-induced DNA damage |
|
| dc.type |
info:eu-repo/semantics/article |
|